 James Liu
Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Estrogens | 8 | 2020 | 312 | 2.740 |
Why?
| | Postmenopause | 6 | 2021 | 303 | 1.480 |
Why?
| | Leiomyoma | 3 | 2021 | 44 | 1.480 |
Why?
| | Norpregnadienes | 2 | 2021 | 7 | 1.390 |
Why?
| | Vaginal Creams, Foams, and Jellies | 2 | 2018 | 6 | 1.200 |
Why?
| | Dyspareunia | 2 | 2018 | 8 | 1.200 |
Why?
| | Vulva | 2 | 2018 | 24 | 1.190 |
Why?
| | Estrogen Replacement Therapy | 6 | 2020 | 116 | 1.160 |
Why?
| | Estradiol | 4 | 2021 | 455 | 1.130 |
Why?
| | Vagina | 4 | 2021 | 146 | 1.120 |
Why?
| | Ovary | 4 | 2020 | 191 | 0.890 |
Why?
| | Ovarian Neoplasms | 3 | 2020 | 388 | 0.840 |
Why?
| | Intracranial Arteriovenous Malformations | 1 | 2023 | 51 | 0.830 |
Why?
| | Contraceptive Devices, Female | 1 | 2021 | 9 | 0.750 |
Why?
| | Pregnenediones | 1 | 2021 | 21 | 0.740 |
Why?
| | Uterine Neoplasms | 2 | 2018 | 73 | 0.720 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2020 | 9 | 0.710 |
Why?
| | Hormone Antagonists | 1 | 2020 | 33 | 0.700 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 11 | 0.700 |
Why?
| | Menopause, Premature | 1 | 2020 | 8 | 0.700 |
Why?
| | Antineoplastic Agents, Hormonal | 2 | 2018 | 138 | 0.680 |
Why?
| | Breast Neoplasms | 2 | 2020 | 1862 | 0.640 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2020 | 188 | 0.630 |
Why?
| | Androgen Antagonists | 1 | 2019 | 69 | 0.620 |
Why?
| | Uterine Hemorrhage | 1 | 2018 | 34 | 0.620 |
Why?
| | Hysterectomy | 2 | 2018 | 106 | 0.590 |
Why?
| | Vaginal Diseases | 1 | 2017 | 17 | 0.590 |
Why?
| | Osteoporosis | 1 | 2020 | 226 | 0.580 |
Why?
| | Pyrimidines | 1 | 2020 | 376 | 0.570 |
Why?
| | Cardiovascular System | 1 | 2018 | 125 | 0.540 |
Why?
| | Transgender Persons | 1 | 2019 | 134 | 0.540 |
Why?
| | Testosterone | 2 | 2019 | 343 | 0.540 |
Why?
| | Double-Blind Method | 6 | 2021 | 1660 | 0.460 |
Why?
| | Pituitary Neoplasms | 3 | 2015 | 157 | 0.460 |
Why?
| | Pneumocephalus | 1 | 2013 | 1 | 0.430 |
Why?
| | Female | 26 | 2023 | 59466 | 0.400 |
Why?
| | Reproductive Medicine | 1 | 2012 | 15 | 0.400 |
Why?
| | Estrogens, Conjugated (USP) | 1 | 2012 | 34 | 0.390 |
Why?
| | Hot Flashes | 1 | 2012 | 72 | 0.370 |
Why?
| | Endocrinology | 1 | 2012 | 70 | 0.370 |
Why?
| | Atrophy | 4 | 2021 | 152 | 0.360 |
Why?
| | Endoscopy | 1 | 2013 | 246 | 0.360 |
Why?
| | Adenoma | 2 | 2015 | 189 | 0.350 |
Why?
| | Sleep Deprivation | 1 | 2012 | 166 | 0.340 |
Why?
| | Humans | 30 | 2023 | 114623 | 0.320 |
Why?
| | Ovarian Hyperstimulation Syndrome | 1 | 2007 | 6 | 0.280 |
Why?
| | Gonadotropins, Pituitary | 1 | 2007 | 22 | 0.280 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 511 | 0.270 |
Why?
| | Postoperative Complications | 2 | 2015 | 2128 | 0.260 |
Why?
| | Follicle Stimulating Hormone | 1 | 2007 | 216 | 0.260 |
Why?
| | Administration, Intravaginal | 4 | 2021 | 20 | 0.240 |
Why?
| | Drainage | 2 | 2015 | 151 | 0.220 |
Why?
| | Craniotomy | 1 | 2023 | 68 | 0.210 |
Why?
| | Menopause | 2 | 2015 | 271 | 0.200 |
Why?
| | Middle Aged | 10 | 2018 | 26719 | 0.200 |
Why?
| | Wakefulness | 1 | 2023 | 128 | 0.200 |
Why?
| | Skull Base | 1 | 2022 | 39 | 0.200 |
Why?
| | Progesterone | 2 | 2021 | 232 | 0.200 |
Why?
| | Intraoperative Complications | 1 | 2023 | 122 | 0.200 |
Why?
| | Skull Base Neoplasms | 1 | 2022 | 24 | 0.200 |
Why?
| | Treatment Outcome | 5 | 2023 | 9084 | 0.190 |
Why?
| | Ethinyl Estradiol | 1 | 2021 | 17 | 0.190 |
Why?
| | Endometrium | 2 | 2015 | 60 | 0.190 |
Why?
| | Adult | 11 | 2023 | 30528 | 0.180 |
Why?
| | Phytoestrogens | 1 | 2020 | 13 | 0.180 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2020 | 26 | 0.180 |
Why?
| | Contraceptive Agents | 1 | 2021 | 54 | 0.180 |
Why?
| | Genes, BRCA2 | 1 | 2020 | 24 | 0.170 |
Why?
| | Pregnancy | 5 | 2021 | 5517 | 0.170 |
Why?
| | Genes, BRCA1 | 1 | 2020 | 31 | 0.170 |
Why?
| | Drug Combinations | 1 | 2021 | 287 | 0.170 |
Why?
| | Seizures | 1 | 2023 | 340 | 0.170 |
Why?
| | Neuroprotection | 1 | 2019 | 30 | 0.170 |
Why?
| | Sex Reassignment Procedures | 1 | 2019 | 3 | 0.170 |
Why?
| | Amenorrhea | 1 | 2018 | 27 | 0.160 |
Why?
| | Pruritus Vulvae | 1 | 2018 | 1 | 0.150 |
Why?
| | Candidiasis, Vulvovaginal | 1 | 2018 | 4 | 0.150 |
Why?
| | Administration, Oral | 1 | 2020 | 728 | 0.150 |
Why?
| | Receptors, Progesterone | 2 | 2021 | 319 | 0.150 |
Why?
| | Administration, Topical | 1 | 2018 | 138 | 0.150 |
Why?
| | Symptom Assessment | 1 | 2018 | 119 | 0.140 |
Why?
| | Sinus Pericranii | 1 | 2016 | 1 | 0.140 |
Why?
| | Superior Sagittal Sinus | 1 | 2016 | 3 | 0.140 |
Why?
| | Cross-Over Studies | 1 | 2018 | 440 | 0.140 |
Why?
| | Transverse Sinuses | 1 | 2016 | 8 | 0.140 |
Why?
| | Algorithms | 2 | 2015 | 1466 | 0.130 |
Why?
| | Decorin | 1 | 2015 | 6 | 0.130 |
Why?
| | Meningioma | 1 | 2016 | 77 | 0.130 |
Why?
| | Meningeal Neoplasms | 1 | 2016 | 87 | 0.130 |
Why?
| | Peritoneum | 1 | 2015 | 36 | 0.120 |
Why?
| | Myometrium | 1 | 2015 | 35 | 0.120 |
Why?
| | Natural Orifice Endoscopic Surgery | 1 | 2015 | 26 | 0.120 |
Why?
| | Cerebrospinal Fluid Leak | 1 | 2015 | 28 | 0.120 |
Why?
| | Decision Making, Computer-Assisted | 1 | 2015 | 18 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1342 | 0.120 |
Why?
| | Proteoglycans | 1 | 2015 | 107 | 0.120 |
Why?
| | Hormone Replacement Therapy | 1 | 2015 | 77 | 0.120 |
Why?
| | Endometriosis | 1 | 2015 | 40 | 0.120 |
Why?
| | Product Labeling | 1 | 2014 | 5 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2023 | 4411 | 0.120 |
Why?
| | Optic Chiasm | 1 | 2013 | 18 | 0.110 |
Why?
| | Cerebral Ventricles | 1 | 2013 | 47 | 0.110 |
Why?
| | Mobile Applications | 1 | 2015 | 140 | 0.100 |
Why?
| | Cognition | 1 | 2019 | 988 | 0.100 |
Why?
| | Fertility Agents, Female | 1 | 2012 | 19 | 0.100 |
Why?
| | Triptorelin Pamoate | 1 | 2012 | 19 | 0.100 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2012 | 30 | 0.100 |
Why?
| | Pregnancy, Ectopic | 1 | 2012 | 51 | 0.100 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 78 | 0.100 |
Why?
| | Vasomotor System | 1 | 2012 | 39 | 0.100 |
Why?
| | Surgical Flaps | 1 | 2013 | 121 | 0.100 |
Why?
| | Spermatocidal Agents | 1 | 2010 | 5 | 0.090 |
Why?
| | Nonoxynol | 1 | 2010 | 4 | 0.090 |
Why?
| | Weight Reduction Programs | 1 | 2012 | 94 | 0.090 |
Why?
| | Aged | 4 | 2018 | 19061 | 0.090 |
Why?
| | Betaine | 1 | 2010 | 63 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2537 | 0.090 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2010 | 84 | 0.090 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4620 | 0.080 |
Why?
| | Nose | 2 | 2022 | 55 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2023 | 12542 | 0.080 |
Why?
| | Cohort Studies | 1 | 2018 | 4894 | 0.080 |
Why?
| | Ovulation | 1 | 2008 | 39 | 0.080 |
Why?
| | Luteal Phase | 1 | 2008 | 41 | 0.080 |
Why?
| | Quality of Life | 1 | 2018 | 2353 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 577 | 0.070 |
Why?
| | Gynatresia | 1 | 2006 | 1 | 0.070 |
Why?
| | Fertility | 1 | 2007 | 130 | 0.060 |
Why?
| | Infertility, Female | 1 | 2006 | 94 | 0.060 |
Why?
| | Mental Disorders | 1 | 2013 | 892 | 0.060 |
Why?
| | Surrogate Mothers | 1 | 2004 | 2 | 0.060 |
Why?
| | Embryo Transfer | 1 | 2004 | 29 | 0.060 |
Why?
| | Ovulation Induction | 1 | 2004 | 49 | 0.060 |
Why?
| | Vasodilator Agents | 1 | 2006 | 302 | 0.060 |
Why?
| | Infertility | 1 | 2004 | 45 | 0.060 |
Why?
| | Piperazines | 1 | 2006 | 309 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2279 | 0.060 |
Why?
| | Ultrasonography | 1 | 2007 | 633 | 0.050 |
Why?
| | Risk Factors | 2 | 2015 | 8628 | 0.050 |
Why?
| | Otolaryngologists | 1 | 2022 | 10 | 0.050 |
Why?
| | Biomarkers | 1 | 2012 | 3408 | 0.050 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3039 | 0.050 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2004 | 216 | 0.050 |
Why?
| | Male | 3 | 2023 | 55554 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2012 | 1879 | 0.050 |
Why?
| | Neurosurgical Procedures | 1 | 2022 | 152 | 0.050 |
Why?
| | Obesity | 1 | 2012 | 2507 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2021 | 144 | 0.040 |
Why?
| | Aging | 1 | 2008 | 1618 | 0.040 |
Why?
| | Angiography, Digital Subtraction | 1 | 2016 | 44 | 0.030 |
Why?
| | Promegestone | 1 | 2015 | 33 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 2015 | 133 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 172 | 0.030 |
Why?
| | Income | 1 | 2015 | 167 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2015 | 338 | 0.030 |
Why?
| | Endometrial Neoplasms | 1 | 2015 | 141 | 0.030 |
Why?
| | Educational Status | 1 | 2015 | 412 | 0.030 |
Why?
| | Blotting, Western | 1 | 2015 | 1147 | 0.030 |
Why?
| | Biopsy | 1 | 2015 | 1036 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 663 | 0.020 |
Why?
| | Laparoscopy | 1 | 2015 | 398 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2015 | 1629 | 0.020 |
Why?
| | Gels | 1 | 2010 | 72 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 2710 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 2894 | 0.020 |
Why?
| | Decision Making | 1 | 2015 | 782 | 0.020 |
Why?
| | Pregnanediol | 1 | 2008 | 12 | 0.020 |
Why?
| | Estrone | 1 | 2008 | 35 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3003 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2186 | 0.020 |
Why?
| | Young Adult | 2 | 2015 | 10455 | 0.020 |
Why?
| | Sildenafil Citrate | 1 | 2006 | 57 | 0.020 |
Why?
| | Sulfones | 1 | 2006 | 97 | 0.020 |
Why?
| | Purines | 1 | 2006 | 159 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6344 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 6217 | 0.010 |
Why?
| | Women's Health | 1 | 2006 | 271 | 0.010 |
Why?
| | United States | 1 | 2015 | 12176 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 4405 | 0.010 |
Why?
| | Adolescent | 1 | 2010 | 17831 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|